The updated rating of the companies ranked by sales level of RX drugs in 2018 has not brought any dramatic changes as compared with the previous year. The TOP 5 companies have not changed; some just swapped their places.

Pfizer with a sales volume of $ 45.3 billion remains the number one company. Roche and Novartis having the sales level of $44,55 billion and of $43,48 billion correspondingly swapped their places.

Johnson & Johnson with a sales volume of $38,81 billion has found itself in the fourth place by driving out Merck & Co. to the fifth position with $37,35 billion sales level.

Sanofi was ranked the sixth with the sales level of $35,12 billion, followed by AbbVie with $ 32,07 billion taking seventh place. GlaxoSmithKline and Amgen were ranked eighth and ninth having the sales level of $30,64 billion and $22,53 billion correspondently.

Gilead Sciences with the sales level $21,68 billion is in the 10th position. In the rating of 2017, this position was taken by Amgen.

Such giants as Bristol-Myers Squibb, AstraZeneca, Allergan, Takeda, and Teva wasn’t listed amongst the TOP 10 companies in 2018 by sales level of RX drugs and occupy the places from eleventh to twentieth

BaDM - We work for you!

Regional offices